{"nctId":"NCT00264537","briefTitle":"A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive","startDateStruct":{"date":"2005-12"},"conditions":["Rheumatoid Arthritis"],"count":637,"armGroups":[{"label":"Group 1: Placebo + Methotrexate","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo injections","Drug: Methotrexate capsules","Biological: Golimumab 50 mg injections","Biological: Golimumab 100 mg injections"]},{"label":"Group 2: Golimumab 100 mg + Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo capsules","Drug: Methotrexate capsules","Biological: Golimumab 50 mg injections","Biological: Golimumab 100 mg injections"]},{"label":"Group 3: Golimumab 50 mg + Methotrexate","type":"EXPERIMENTAL","interventionNames":["Drug: Methotrexate capsules","Biological: Golimumab 50 mg injections","Biological: Golimumab 100 mg injections"]},{"label":"Group 4: Golimumab 100 mg + Methotrexate","type":"EXPERIMENTAL","interventionNames":["Drug: Methotrexate capsules","Biological: Golimumab 50 mg injections","Biological: Golimumab 100 mg injections"]}],"interventions":[{"name":"Placebo injections","otherNames":[]},{"name":"Placebo capsules","otherNames":[]},{"name":"Methotrexate capsules","otherNames":[]},{"name":"Golimumab 50 mg injections","otherNames":[]},{"name":"Golimumab 100 mg injections","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a diagnosis of rheumatoid arthritis (RA) (according to the revised 1987 criteria of the ACR) for at least 3 months prior to first administration of study agent\n* Are methotrexate (MTX)-naÃ¯ve (ie, have not received more than 3 weekly doses of MTX for RA at any time)\n* Have active RA as defined by persistent disease activity with at least 4 swollen and 4 tender joints, at the time of screening and baseline, and at least 2 of the following 4 criteria: a) C-reactive protein (CRP) \\>=1.5 mg/dL at screening or erythrocyte sedimentation rate (ESR) by Westergren method of \\>= 28 mm in the first hour at screening or baseline, b)Morning stiffness of \\>= 30 minutes at screening and baseline, c)Bone erosion by x-ray and/or MRI prior to first administration of study agent, d)Anti-cyclic citrullinated peptide (anti-CCP) antibody-positive or rheumatoid factor (RF) positive at screening\n* If using oral corticosteroids, must be on a stable dose equivalent to \\<= 10 mg of prednisone/day for at least 2 weeks prior to first administration of study agent.\n\nExclusion Criteria:\n\n* Can not have inflammatory diseases other than RA that might confound the evaluation of the benefit of golimumab therapy\n* No treatment with disease-modifying anti-rheumatic drugs (DMARDs)/systemic immunosuppressives during the 4 weeks prior to the first administration of study agent\n* No prior treatment with biologic anti-TNF drugs (infliximab, etanercept, adalimumab)\n* No history of, or ongoing, chronic or recurrent infectious disease\n* No serious infection within 2 months prior to first administration of study agent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24","description":"ACR 50 response is defined as a greater than or equal to 50 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain by the Visual Analogue Scale (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity VAS (0-10 cm) c. Physician's Global Assessment of Disease Activity VAS (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"64","spread":null},{"groupId":"OG003","value":"58","spread":null},{"groupId":"OG004","value":"122","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 24","description":"ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 20 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain by the Visual Analogue Scale (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity VAS (0-10 cm) c. Physician's Global Assessment of Disease Activity VAS (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"98","spread":null},{"groupId":"OG004","value":"196","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Abnormal Baseline C-reactive Protein (CRP) Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24","description":"ACR 50 response is defined as a greater than or equal to 50 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain by the Visual Analogue Scale (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity VAS (0-10 cm) c. Physician's Global Assessment of Disease Activity VAS (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"37","spread":null},{"groupId":"OG004","value":"75","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 52","description":"The vdH-S score is the sum of the joint erosion score and the joint-space narrowing (JSN) score. The total score ranges from 0 (best) to 448 (worst) with higher scores indicating more joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.37","spread":"4.555"},{"groupId":"OG001","value":"1.25","spread":"6.155"},{"groupId":"OG002","value":"0.74","spread":"5.233"},{"groupId":"OG003","value":"0.07","spread":"1.833"},{"groupId":"OG004","value":"0.41","spread":"3.929"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 52 in Patients With Abnormal C-reactive Protein (CRP Greater Than 1.0 mg/dL) at Baseline","description":"The vdH-S score is the sum of the joint erosion score and the joint-space narrowing (JSN) score. The total score ranges from 0 (best) to 448 (worst) with higher scores indicating more joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.16","spread":"5.642"},{"groupId":"OG001","value":"2.19","spread":"7.967"},{"groupId":"OG002","value":"1.29","spread":"6.991"},{"groupId":"OG003","value":"0.16","spread":"2.195"},{"groupId":"OG004","value":"0.74","spread":"5.235"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":55,"n":172},"commonTop":["Upper Respiratory Tract Infection","Nausea","Bronchitis","Alanine Aminotransferase Increased","Cough"]}}}